β3-adrenoreceptor stimulation protects against myocardial infarction injury via eNOS and nNOS activation

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Niu, Xiaolin ^a   Zhao, Lianyou ^a   Li, Xue ^a   Xue, Yusheng ^a   Wang, Bin ^a   Lv, Zongqiang ^c   Chen, Jianghong ^a   Sun, Dongdong ^b   Zheng, Qiangsun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; BETA 3 ADRENERGIC RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; ENZYME ACTIVATION; ETHANOLAMINES; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION;

EID: 84902590382     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098713     Document Type: Article

References (39)

1. Roger VL, Jacobsen SJ, Weston SA, Goraya TY, Killian J, et al. (2002) Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med 136: 341-348. (Pubitemid 34183992)
2. Braunwald E, Bristow MR (2000) Congestive heart failure: fifty years of progress. Circulation 102: IV14-23.
3. Dec GW, Fuster V (1994) Idiopathic dilated cardiomyopathy. N Engl J Med 331: 1564-1575. (Pubitemid 24366905)
4. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, et al. (2003) Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107: 2459-2466. (Pubitemid 36605229)
5. Communal C, Singh K, Sawyer DB, Colucci WS (1999) Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100: 2210-2212.
6. Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, et al. (1991) Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J 10: 3721-3727. (Pubitemid 21905399)
7. Simard PM, Atgie C, Mauriege P, D'Allaire F, Bukowiecki LJ (1994) Comparison of the lipolytic effects of norepinephrine and BRL 37344 in rat brown and white adipocytes. Obes Res 2: 424-431.
8. Rozec B, Noireaud J, Trochu JN, Gauthier C (2003) Place of beta 3- adrenoceptors among other beta-adrenoceptor subtypes in the regulation of the cardiovascular system. Arch Mal Coeur Vaiss 96: 905-913. (Pubitemid 37203737)
9. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H (1996) Functional beta3-adrenoceptor in the human heart. J Clin Invest 98: 556-562.
10. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, et al. (2009) Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. J Mol Cell Cardiol 47: 576-585.
11. Rozec B, Gauthier C (2006) beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 111: 652-673. (Pubitemid 44137382)
12. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, et al. (2001) Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103: 1649-1655. (Pubitemid 32246612)
13. Varghese P, Harrison RW, Lofthouse RA, Georgakopoulos D, Berkowitz DE, et al. (2000) beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest 106: 697-703.
14. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, et al. (1998) The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102: 1377-1384. (Pubitemid 28467566)
15. Napp A, Brixius K, Pott C, Ziskoven C, Boelck B, et al. (2009) Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium. J Card Fail 15: 57-67.
16. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, et al. (2012) Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol 59: 1979-1987.
17. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, et al. (2010) A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 107: 1445-1453.
18. Zhang Z, Li S, Cui M, Gao X, Sun D, et al. (2013) Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Basic Res Cardiol 108: 333.
19. Sun D, Huang J, Zhang Z, Gao H, Li J, et al. (2012) Luteolin limits infarct size and improves cardiac function after myocardium ischemia/reperfusion injury in diabetic rats. PLoS One 7: e33491.
20. Zhang Z, Li W, Sun D, Zhao L, Zhang R, et al. (2011) Toll-like receptor 4 signaling in dysfunction of cardiac microvascular endothelial cells under hypoxia/reoxygenation. Inflamm Res 60: 37-45.
21. Balligand JL (2009) beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?". J Am Coll Cardiol 53: 1539-1542.
22. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369: 151-159. (Pubitemid 38270770)
23. Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C (2009) Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 53: 1532-1538.
24. Aragon JP, Condit ME, Bhushan S, Predmore BL, Patel SS, et al. (2011) Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol 58: 2683-2691.
25. Brixius K, Bloch W, Ziskoven C, Bolck B, Napp A, et al. (2006) Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium. Can J Physiol Pharmacol 84: 1051-1060.
26. Schulz R, Kelm M, Heusch G (2004) Nitric oxide in myocardial ischemia/ reperfusion injury. Cardiovasc Res 61: 402-413. (Pubitemid 38210147)
27. Sharp BR, Jones SP, Rimmer DM, Lefer DJ (2002) Differential response to myocardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol 282: H2422-2426. (Pubitemid 34663055)
28. Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118: 1915-1919.
29. Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, et al. (2005) Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation 112: 3415-3422. (Pubitemid 43739556)
30. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, et al. (2005) nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation 112: 3729-3737. (Pubitemid 43739513)
31. Kolluru GK, Siamwala JH, Chatterjee S (2010) eNOS phosphorylation in health and disease. Biochimie 92: 1186-1198.
32. Mount PF, Kemp BE, Power DA (2007) Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 42: 271-279. (Pubitemid 46135596)
33. Fleming I, Busse R (2003) Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284: R1-12.
34. Damy T, Ratajczak P, Shah AM, Camors E, Marty I, et al. (2004) Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 363: 1365-1367. (Pubitemid 38529877)
35. Bendall JK, Damy T, Ratajczak P, Loyer X, Monceau V, et al. (2004) Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in betaadrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 110: 2368-2375. (Pubitemid 39407341)
36. Mishra OP, Ashraf QM, Delivoria-Papadopoulos M (2009) Tyrosine phosphorylation of neuronal nitric oxide synthase (nNOS) during hypoxia in the cerebral cortex of newborn piglets: the role of nitric oxide. Neurosci Lett 462: 64-67.
37. Rameau GA, Chiu LY, Ziff EB (2003) NMDA receptor regulation of nNOS phosphorylation and induction of neuron death. Neurobiol Aging 24: 1123-1133. (Pubitemid 37487890)
38. Calvert JW, Condit ME, Aragon JP, Nicholson CK, Moody BF, et al. (2011) Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res 108: 1448-1458.
39. Brixius K, Bloch W, Pott C, Napp A, Krahwinkel A, et al. (2004) Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol 143: 1014-1022. (Pubitemid 40065502)